Robert L. Scavo, Chief Information Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), completed two share sales on March 12, 2026, disposing of a total of 4,044 common shares for aggregate proceeds of $70,554.
The transactions were split into two tranches. The larger block comprised 3,799 shares sold at a weighted average price of $17.476 per share, with individual sale prices in that tranche ranging from $17.035 to $18.03. The smaller transaction involved 245 shares sold at a weighted average price of $16.9919 per share, with execution prices ranging from $16.92 to $17.03.
According to the Form 4 disclosure, these dispositions were undertaken to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and were not discretionary trades by Scavo. After these sales, Scavo directly holds 498,970 shares of Alignment Healthcare.
The share sales come as Alignment Healthcare stock has softened in the market. The company’s share price has slipped nearly 8% over the past week and is down roughly 14% year-to-date, trading around $17 per share at the time of the disclosure. An InvestingPro analysis referenced in the filing indicates a Fair Value estimate of $19.98 for the stock at current levels.
While the company did not post a profit over the trailing twelve months, the filing notes that analysts forecast a return to profitability this year. The filing also points readers toward additional InvestingPro commentary and tools that offer deeper research, including ProTips and a Pro Research Report.
Separately, Alignment Healthcare disclosed a secondary sale by an affiliate of General Atlantic, L.P. The affiliate has priced 13.2 million shares at $19.46 per share, and Alignment Healthcare confirmed it will receive no proceeds from that transaction. The offering was expected to close on March 4, 2026, subject to customary closing conditions, with J.P. Morgan acting as the underwriter.
Market commentary accompanying the corporate activity includes analyst actions and targets that reflect varied sentiment. Raymond James reiterated a Strong Buy rating and assigned a $27.00 price target after the company reported fourth-quarter results that outpaced expectations. Those results included year-over-year membership growth of approximately 25% and revenue growth of about 44.4%. Piper Sandler also maintained an Overweight rating with a $30.00 price target, noting the company’s strong fourth-quarter performance in 2025.
This sequence of insider selling for tax purposes, a substantial secondary sale by a major affiliate, and contrasting analyst endorsements frames the current public equity picture for Alignment Healthcare. Each element is presented in the company’s disclosures and associated analyst notes without indicating a direct causal relationship between the items.
Investors seeking more exhaustive datasets and additional analyst commentary are directed to the referenced Pro Research materials noted in the disclosure.